RAREUltragenyx Pharmaceutical Inc.
Is it safe?
Elevated bankruptcy risk: a balance sheet under strain, heavy debt (CCC), and big price swings. Everything else is secondary until this clears.
Elevated financial-distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.
Insiders were net sellers (-$184K, 90 days to Oct 8, 2026), selling is often routine.
Debt against weak or negative operating profit. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -93% · now 58% below its 52-week high.
Unless marked, from SEC EDGAR, as of Dec 31, 2025.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can RARE take a bad year?
The deepest fall in RARE's price history on file is −93%; it is 58% below its high today.
Altman Z-score · distress below 1.8 · safe above 3 · distress zone, the model puts this in the bankruptcy range
- Cash runway
- 0.6 years
Cash runway · burning $122M a quarter at the current rate
- Annualised volatility
- 67%
Annualised volatility · three times the market's own swing
- Worst drawdown on file
- −93%
Worst drawdown on file · −58% today
Details›
- Cash and short-term investments
- $292M
- EBITDA, trailing twelve months
- −$495M
- Operating profit, trailing twelve months
- −$528M
- Annualised volatilitytwo years of daily moves
- 67%
- Worst drawdown on file
- −93%
- Below its 52-week high
- 58%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.